Savara (SVRA) Total Current Liabilities (2010 - 2026)
Savara (SVRA) posted quarterly Total Current Liabilities of $15.5 million for Q1 2026, up 30.6% year-over-year from $11.9 million in Q1 2025, and down 23.81% quarter-over-quarter from $20.4 million in Q4 2025.
Savara (SVRA) Total Current Liabilities (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Total Current Liabilities for 17 consecutive years, with $15.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 30.6% year-over-year to $15.5 million; the TTM figure through Mar 2026 stood at $15.5 million (up 30.6% YoY), while the FY2025 annual figure was $20.4 million, up 38.52% from the prior year.
- Total Current Liabilities retreated to $15.5 million in Q1 2026 per SVRA's latest filing, from $20.4 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $20.4 million in Q4 2025 and bottomed at $3.7 million in Q2 2022.
- Historically, Total Current Liabilities has averaged $11.1 million across 5 years, with a median of $11.3 million in 2024.
- Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 126.49% — and 2023, when it sank 69.85%.
- Savara's Total Current Liabilities stood at $5.9 million in 2022, then surged by 80.62% to $10.6 million in 2023, then surged by 38.94% to $14.7 million in 2024, then jumped by 38.52% to $20.4 million in 2025, then retreated by 23.81% to $15.5 million in 2026.
- Business Quant data shows SVRA's Total Current Liabilities at $15.5 million in Q1 2026, $20.4 million in Q4 2025, and $16.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | 17.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.60 Mn |
| Mar 31, 2026 | 15.54 Mn |
| Dec 31, 2025 | 20.40 Mn |
| Sep 30, 2025 | 16.76 Mn |
| Jun 30, 2025 | 13.63 Mn |
| Mar 31, 2025 | 11.90 Mn |
| Dec 31, 2024 | 14.72 Mn |
| Sep 30, 2024 | 12.79 Mn |
| Jun 30, 2024 | 11.29 Mn |
| Mar 31, 2024 | 9.81 Mn |
| Dec 31, 2023 | 10.60 Mn |
| Sep 30, 2023 | 8.96 Mn |
| Jun 30, 2023 | 5.89 Mn |
| Mar 31, 2023 | 4.92 Mn |
| Dec 31, 2022 | 5.87 Mn |
| Sep 30, 2022 | 5.16 Mn |
| Jun 30, 2022 | 3.71 Mn |
| Mar 31, 2022 | 16.32 Mn |
| Dec 31, 2021 | 14.66 Mn |
| Sep 30, 2021 | 10.66 Mn |